Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes ...

Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.

Sanofi has also exercised its option to select a third SAFEbody discovery program, utilizing Adagene’s proprietary masking technology and antibody engineering expertise.

Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma ...

Sanofi exercises option on Adagene’s SAFEbody program, investing $25 million and sponsoring a clinical trial for muzastotug.

As part of their expanded collaboration, Adagene will provide Sanofi with muzastotug for a phase 1/2 clinical trial to assess its safety and efficacy in combination with other anticancer therapies.

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...